AACR20: atezolizumab combination therapy shows promise in advanced BRAF+ melanoma

Written by Rachel Jenkins, Future Science Group

Due to be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting I (27–28 April 2020), an international team of researchers investigated whether an immune checkpoint inhibitor (ICI) combined with two targeted therapies could improve efficacy in BRAFV600 mutation-positive melanoma, compared with targeted therapy alone. The Phase III trial (NCT02908672), termed IMspire150, included 514 treatment-naïve patients with unresectable Stage IIIc/IV melanoma, measurable disease by RECIST 1.1 and BRAFV600 mutations. Participants were randomized to one of two trial arms. Want regular AACR updates straight to your inbox? Become a member of Oncology Central.   The first arm (256...

To view this content, please register now for access

It's completely free